Access cutting-edge advanced cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access advanced cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced cancer treatment provided free
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 thera
Sponsor: Ascendis Pharma Oncology Division A/S
Check if you qualify for this advanced cancer clinical trial in New York, NY
If you're searching for advanced cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.